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1. Introduction 
 
1.1 Mitochondria 
 
Mitochondria are 0.5-1.0 micron organelles, first described by Richard Altmann in 1890. 
They are enclosed in a double membrane, the outer and inner membrane, separating the 
mitochondrial matrix from the surrounding cytoplasm. The outer mitochondrial membrane 
(OMM) is smooth and interspersed with voltage-dependent anion channels (VDAC), also 
called porins, which provide tunnels for the passage of small ions, metabolites and proteins 
(~5kDa) into the intermembrane space between the outer and inner membrane [1]. In 
comparison to the outer membrane, the inner mitochondrial membrane (IMM) is less 
permeable and highly invaginated, folding many times to create layered structures termed 
cristae, which increase the surface area of the membrane for various chemical reactions. The 
mitochondrial matrix lies within the inner membrane and contains a variety of enzymes and 
proteins responsible for the bioenergetic and biosynthetic pathways of ATP, mitochondrial 
ribosomes, tRNAs and mitochondrial DNA (mtDNA) [2]. 
 
1.1.1 Evolution of mitochondria 
 
Mitochondria are the only organelles containing DNA independent of the nuclear-enclosed 
chromosomal DNA (nDNA) in animal cells. To better understand the mitochondrial genome 
and related proteins, the events resulting in the mitochondria becoming a relatively 
independent part of the eukaryotic cell need to be discussed. 
 
The endosymbiotic theory, as a model for explaining mitochondrial origin, arose in the 
nineteenth century [3]. According to this theory, mitochondria evolved from free-living 
bacteria which were incorporated into eukaryotic host cells via the process of endocytosis  [3, 
4]. And indeed, it is strongly supported by gene sequence data that the monophyletic origin of 
mitochondria from a common eukaryotic ancestor, a subgroup of the α-Proteobacteria, 
emerged more than two billion years ago [5]. The proliferation of mitochondrial proteins is 
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therefore coordinated by the mitochondria’s own cycle in a similar manner to bacterial 
division. However, due to redundancy, the majority of endosymbiotic genes of the 
mitochondria and plastids have been lost in the past two billion years. [6] As a consequence, 
while the nuclear genome has become diverse and more complex, the mitochondria have 
retained just a small number of genes in their genome. Accordingly, analysis of mitochondrial 
proteomes demonstrates that only 22% of human mitochondrial proteins are kept from 
protomitochondrial descent [6]. 
 
1.1.2 Mitochondria and oxidative phosphorylation (OXPHOS) 
 
Mitochondria provide the essential biological energy to cells by continual generation of 
adenosine triphosphate (ATP) via respiratory chain oxidative phosphorylation (OXPHOS). 
The mitochondria are therefore referred to as the cellular energy factories. The mitochondrial 
respiratory chain, otherwise known as the electron transport chain (ETC), is comprised of five 
enzyme complexes residing in the IMM (Figure 1.1). The production of ATP requires a 
constant supply of mitochondrial respiratory substrates, adenosine diphosphate (ADP) and 
inorganic phosphate (Pi). The carrier family proteins of the mitochondria, such as ADP-ATP 
translocase, phosphate carrier protein and citrate transport protein, constantly work to ensure 
the smooth progress of cellular metabolic processes between the mitochondria and the 
cytoplasm [7, 8]. 
 
The mitochondrial respiratory chain generates a electrochemical proton gradient between the 
mitochondrial matrix and the intermembrane space by the transfer of electrons along the 
respiratory chain complexes, and the eventual transfer to molecular oxygen (O2). In brief, the 
reduction equivalents (NADH and FADH2) from glycolysis, the tricarboxylic acid (TCA) 
cycle and from β-oxidation, release their electrons for uptake by the respiratory chain [9]. The 
electron transfer of the respiratory chain is enabled by various prosthetic groups, such as iron-
sulfur (Fe-S) clusters in complex I, II and III and by the heme group in cytochrome C and 
complex IV. In complex I (NADH dehydrogenase) electrons are delivered from the oxidation 
of NADH, in complex II (succinate dehydrogenase) from the oxidation of succinate via flavin 
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adenine dinucleotide (FAD), and additionally, electron transfer flavoprotein (ETF) transfers 
electrons originating from β-oxidation to the electron transport chain. After the electrons 
access the respiratory chain, the lipophilic molecule coenzyme Q (CoQ) is reduced from its 
ubiquinone form to ubiquinol. The electrons pass to complex III (cytochrome C reductase) 
which in turn transfers them to cytochrome C. The water-soluble protein cytochrome C 
shuttles electrons in the IMS between respiratory chain complexes III and IV, the cytochrome 
oxidase (COX). COX catalyzes the final reaction, the reduction of O2 to water and thus 
generates the electrochemical gradient. 
 
Through this transfer of electrons, the process of oxidative phosphorylation (OXPHOS) leads 
to the active pumping of hydrogen ions across the IMM to the intermembrane space, and the 
resulting electrochemical proton gradient drives the synthesis of ATP from ADP and 
inorganic phosphate (Pi) by complex V (ATP-synthase) [10]. The synthesized ATP can 
subsequently be used for all active metabolic processes. 
 
 
	
Figure	 1.1:	 The	 electron	 transport	 chain	 (ETC).	 	 ETC	 shuttles	 electrons	 from	 NADH	 and	
FADH2	to	O2	(orange	arrows)	forming	H2O	via	four	protein	complexes	(Complex	I-IV)	embedded	
in	 the	 inner	mitochondrial	membrane.	 In	 the	process,	protons	 (H+	ions)	 are	pumped	 from	 the	
mitochondrial	matrix	to	the	intermembrane	space	producing	a	proton	gradient	for	subsequent	
ATP	production	by	Complex	V.	
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1.2 Human mitochondrial genome 
 
Mitochondrion each contain their own small genome, the mitochondrial DNA (mtDNA). In 
1963, Sylvan et al. firstly detected the DNA within mitochondria [11] and in 1981, Anderson 
et al. completed the sequence of the human mitochondrial genome [12]. The human mtDNA 
is a double-stranded circular, 16,569 bp molecule consisting of 37 genes which collectively 
encode 22 transfer RNAs (tRNA), 12S and 16S ribosomal RNAs (rRNA), and 13 core 
OXPHOS polypeptides. The numbers of mitochondria and mitochondrial genomes per cell is 
regulated and is distinct between different tissues [13]. Each mitochondrion typically contains 
2–10 mtDNA copies [14], therefore 100–10,000 separate copies of mtDNA are generally 
estimated per somatic cell depending on the type and developmental stage of cell [14]. 
 
1.2.1 Structure of mtDNA 
 
The structure and gene organization of mammalian mtDNA is highly conserved. It is a closed 
circular double-stranded DNA molecule made up of a H strand (heavy strand) and an L strand 
(light strand). The designations of the strands of the DNA duplex are derived from the 
different buoyant densities due to the asymmetric distribution of guanine and cytosine by the 
CsCl (cesium chloride) equilibrium gradient centrifugation [15]. The map of mammalian 
mtDNA is organized as shown in Figure 1.2. The origins of replication of the H and L strands 
are called as OH and OL respectively, and are significant landmarks of the ring-shaped 
mtDNA. The H strand runs with a 5’→3’ polarity in a counter-clockwise direction, while the 
L stand runs with a clockwise polarity. The section from OH to OL in a clockwise direction is 
termed the large arc, the corresponding section from OL to OH is termed the small arc. 
 
As opposed to nuclear DNA, mtDNA lacks an intron-exon structure. There are only two non-
coding intergenic regions in mtDNA contributing a major component of the regulated 
expression unit. The major non-coding region is commonly known as the displacement loop 
(D-loop) spanning ~1 kb in humans and residing between the genes encoding tRNAPhe and 
tRNAPro, where it contains the OH and the promoters for mtDNA transcription [16]. Here, the 
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two strands of the mtDNA are separated by a third strand. The D-loop is the most variable 
fragment of mtDNA due to high substitution. Given that the D-loop contains highly conserved 
elements with potential regulatory function, this variability increases the potential for 
deleterious mutations to arise [17, 18]. The second, shorter (30 nucleotide-long) non-protein 
coding region, is located around two-thirds of the mtDNA distance from the OH and resides 
within a tRNA cluster, containing OL. 
 
 
 
Figure	1.2:	Structure	of	mitochondrial	DNA.	The	respiratory	chain	complex	genes,	ribosomal	
RNA	genes	and	non-coding	DNA	are	colored	respectively.	The	tRNA	genes	are	designated	by	the	
abbreviation	 of	 the	 corresponding	 amino	 acid.	 The	 abbreviations	 of	 the	 protein-coding	 genes	
describe	the	encoded	subunit	of	the	respective	respiratory	chain	complex.	
 
1.2.2 Inheritance of mtDNA 
 
It is generally considered that the human mtDNA is exclusively maternally inherited. 
However, a single case report of a patient with mitochondrial myopathy and inheritance of a 
pathogenic mtDNA mutation occurring on a paternal mtDNA background has been described 
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[19]. Furthermore, there are several lines of evidence for the rare paternal inheritance of 
mtDNA in other mammalian species [20]. 
 
1.2.3 Transcription products of mtDNA 
 
It has been shown that both mtDNA strands are completely and symmetrically transcribed 
according to in vivo human and mouse cell models in mitochondrial studies. The majority of 
the protein-coding mtDNA genes are located on the H-strand, this includes two genes 
encoding rRNAs (12S and 16S rRNA), 14 genes encoding tRNAs and 12 protein-coding 
genes. Only a small amount of information is encoded on the L-strand, including genes for 
eight tRNAs and 1 protein-encoding gene (ND6). 
 
Taking a closer look at the protein-coding genes (see Figure 1.2), the genes ND1, ND2, ND3, 
ND4, ND4L, ND5 and ND6 encode components of complex I.  In mammals, complex I 
comprises 44 different subunits, seven encoded by mtDNA and 37 encoded by the nuclear 
DNA (nDNA) [21]. All four subunits of complex II are nuclear-encoded. In complex III, 
cytochrome b is the only mtDNA-encoded subunit, with the remaining 9 subunits encoded in 
the nDNA. Complex IV (cytochrome C oxidase) is a complex enzyme composed of 13 
protein subunits. The larger active subunits, cytochrome oxidase (CO) I, II and III, are 
encoded by the mtDNA, with the remaining smaller subunits encoded by the nDNA 
[22]. Finally, the ATPase 6 and ATPase 8 genes, two of the 12 subunits of complex V (ATP 
synthase) are mtDNA-encoded and the remainder are nuclear-encoded. The mitochondrial 
genome therefore encodes rRNA and related tRNA molecules for their own 
intramitochondrial translation, in addition to the minority of the protein components of the 
respiratory complexes, with complex II entirely nDNA-encoded. In Figure. 1.2, the short 
genes for tRNAs can be seen to distribute throughout the entire circular mtDNA and are 
depicted in the figure with the respective amino acid-specific abbreviation. The two rRNA 
genes are found near the D-loop region in the counter-clockwise direction. 
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Mitochondrial protein synthesis therefore requires a plethora of different nuclear-encoded 
molecules, such as ribosomal proteins, ribosome assembly proteins and aminoacyl-tRNA 
synthetases (responsible for loading the  mitochondrial tRNAs with amino acids) in addition 
to RNA polymerase and its transcription factors [23]. Accordingly, most mitochondrial 
translation proteins are encoded in the nucleus, synthesized in the cytosol, and imported into 
mitochondria, to assemble into functional respiratory complexes, allowing the generation of 
ATP through oxidative phosphorylation (OXPHOS). 
 
1.2.4 Expression regulation of mtDNA 
 
The principal function of the mitochondria is to generate the majority of the cellular energy in 
the form of ATP by OXPHOS. The expression of mtDNA is therefore the subject of tight 
regulation which requires the participation and coordination of two distinct genomes, the 
mitochondrial and nuclear genomes. However, the molecular mechanisms involved in 
expression regulation remain poorly understood. The expression of nuclear genes associated 
with mitochondrial function and protection is modulated by mitochondria-to-nucleus 
retrograde signaling mechanisms. These signaling pathways are controlled in part by 
mitochondrial metabolites, including Ca2+, reactive oxygen species (ROS), and ATP [24]. 
Ca2+ is a ubiquitous intracellular signal mediating several cellular pathways, including Ca2+-
dependent PKC, CaMKII-CREB and JNK MAPK signaling pathways, and activation of 
calcineurin (CaN, an activator of NFATc and NF-κB), which are essential for muscle 
formation, growth and regeneration. 
 
Furthermore, evidence shows that regulation of mtDNA expression can be achieved through 
adjusting the redox balance and ATP concentration. During recent decades, it has become 
clear that ROS serves as key signaling molecules in the regulation of biological and 
physiological processes. An extensive number of factors are defined as targets of ROS or 
sensitive to redox stress, such as cell-signaling proteins (NF-κB, MAPKs and PI3K-Akt), 
phospholipases A2 (PLA2), PLC and PlD, calcium channels, tyrosine phosphatases, and a 
number of protein kinases [24, 25], which play a key role as an antioxidant defense against 
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the intake of xenobiotics through the activation of antioxidant responsive elements (ARE). In 
terms of nDNA expression, the nuclear respiratory factor-1 (NRF-1) and NF2 regulate 
nuclear-encoded mitochondrial gene transcription and are necessary to maintain 
mitochondrial activity [26]. Both NRF-1 and NRF-2 can indirectly affect the nuclear 
transcription factor Yin-Yang 1 (YY1) leading to a reduction in the product of ATP/AMP 
ratio [27]. 
 
1.3 Mutations of mtDNA 
 
The mutation rate of mtDNA is estimated to be more than 10 times higher than that of nDNA 
[28]. This results from multiple factors: Firstly, even in the presence of mtDNA repair 
systems, mitochondria are deficient in the ability to completely offset the persistent oxidative 
damage caused by ROS generated from the IMM which is in close proximity to the 
mitochondrial genome. And secondly, there is absence of protective histone molecules.  
 
The first pathogenic mtDNA mutation in a human patient was reported in 1988 [29, 30]. Since 
then, over 300 disease-causing mtDNA mutations have been described, presenting with a 
wide variety of disease phenotypes. 
 
The mutations of mtDNA, most often large deletion/duplication and point mutations, have 
their own unique characteristics. As the mitochondrial genome exists in many hundreds of 
copies in each eukaryotic cell, mutations may either affect all of the mitochondria (termed 
homoplasmy) or more commonly affect only a subset of the mitochondria (termed 
heteroplasmy). Thus, affected patient cells may contain a mixture of both wild-type mtDNA 
and mutated mtDNA, the distribution and proportion of which can vary widely between 
different organs and even between different cells of the same organ [31]. This uneven 
distribution of mutated mtDNA influences the physiological function of affected cells and 
contributes to a mosaic pattern of respiratory chain-deficiency cells in affected tissues. If a 
certain limit of mutational load is exceeded, leading to dysfunction of the respiratory chain, 
the patient will express the phenotype, termed the "threshold effect". The exact level of this 
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threshold is dependent upon the type and location of the mutation in the mitochondrial 
genome. For example, it has been reported that a 90% mutational load is required for some 
tRNA genes and ~60% for some deletion mutations to result in a clinical phenotype [32]. 
 
1.3.1 Classification of mtDNA mutations 
 
Currently, due to the characteristics of mitochondrial inheritance and biogenesis, there is no 
single universal classification standard for mtDNA mutations. Correlation of clinical 
phenotype amongst mutation carriers is considered the most significant reference to estimate 
mtDNA mutation pathogenicity. The variant classification which is most commonly used is 
that presented by Wong J et al. 2012 (Table 1.1) [33]. In this classification, the publicly 
available MITOMAP (http://www.MITOMAP.org/MITOMAP) and the Human 
Mitochondrial Genome Database mtDB (http://www.mtdb.igp.uu.se/) databases are referred 
to. 
 
The discovery of a novel rare mutation in the mtDNA allows the diagnosis of mitochondrial 
disease and subsequent genetic counselling. However, due to the relatively high mutation rate 
of mtDNA, it should be taken into consideration that any novel variant detected by complete 
mitochondrial genome sequencing requires further supporting evidence to determine its 
pathogenicity. For example, correlation in the specific clinical manifestation between 
mutation carriers and targeted sequencing of the patient’s mother and other matrilineal 
relatives will benefit to make further function analyses of pathogenicity. 
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Table 1.1: Criteria for the classification of mtDNA variants by pathogenicity. 
mtDNA 
mutation 
Criteria 
Pathogenic 
variant 
mtDNA contains a variant that is listed in the MITOMAP database as a 
“confirmed mutation” and has been annotated in relation with several 
unrelated patients/families with clinical correlation and/or supporting 
functional evidence of pathogenicity 
Unclassified 
variant 
mtDNA variant meeting at least one of the following criteria: 
1) is a novel variant 
2) is a rare variant listed in MITOMAP as a polymorphism, but not in 
mtDB, or reported in mtDB with a frequency £0.2% 
3) is a rare variant reported in the literature or MITOMAP as a “mutation” 
based on a single family study or a single report without the functional 
evidence of pathogenicity 
Benign variant mtDNA variant reported in the MITOMAP database as a polymorphism, 
with no evidence of disease association in population or family studies and 
is reported in the mtDB with a frequency >0.2% 
 
1.3.2 Mitochondrial diseases due to mtDNA mutations 
 
The first association between mitochondrial dysfunction and a clinical phenotype was 
established in 1962 [21, 34]. Since then, a variety of mitochondrial defects have been 
described. Mitochondrial diseases are multisystem diseases characterized by defects in the 
assembly and function of the mitochondrial respiratory chain. Mutations of both the 
mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) have been identified as leading 
causes of these diseases, amounting to a combined prevalence of adult mitochondrial disease 
of ~1 in 4,300 [35]. As discussed, the vast majority of mitochondrial proteins are encoded by 
the nDNA, therefore diseases caused by mutations in these genes may be inherited in an 
autosomal dominant, autosomal recessive or X-linked manner [36]. Furthermore, age-
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associated neurodegeneration such as in Parkinson`s and Alzheimer`s disease as well as 
physiological aging itself have been associated with mitochondrial dysfunction [37]. 
Mitochondrial diseases due to mutations of nuclear genes in the respiratory chain represent 
the minority of diagnosed mitochondrial disease, however increasingly more nDNA gene 
defects continue to be identified [38]. Considering mtDNA mutations, to date, more than 150 
mtDNA mutations are known to have medical significance. One of the commonly used 
classifications of mitochondrial diseases caused by mtDNA mutations has arisen from recent 
advances in molecular genetics as displayed (Table 1.2) [39]. 
 
The point mutations of mtDNA are generally maternally inherited, this includes tRNA, rRNA 
and protein genes. More than half of disease-related point mutations are found in the tRNA 
genes, which make up less than ten percent of the mitochondrial genome [40]. Common 
diseases resulting from the point mutations in tRNA genes are MERRF and MELAS, in 
which the tRNA-Lys and tRNA-Leu genes are disrupted, respectively. A classic example of 
single-nucleotide mutations in-protein-coding genes is Leigh syndrome, characterized by 
psychomotor developmental delay, ataxia, and muscular hypotonia, with a point mutation in 
the ATPase 6 (MT-ATP6) gene, encoding a subunit of complex V of the respiratory chain. 
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Table 1.2: Genetic classification of mitochondrial diseases caused by mtDNA mutations  
Point mutations in 
protein-coding genes 
• Protein-coding genes 
• Leber hereditary optic neuropathy (LHON) (m.11778G>A, 
m.14484T>C, m.3460G>A) 
• Neurogenic weakness with ataxia and retinitis 
pigmentosa/Leigh syndrome (m.8993T>G, m.8993T>C) 
Point mutations in tRNA 
genes 
• Mitochondrial encephalomyopathy with lactic acidosis and 
stroke-like episodes (MELAS) (m.3243A>G, m.3271T>C, 
m.3251A>G) 
• Myoclonic epilepsy with ragged red fibers (MERRF) 
(m.8344A>G, m.8356T>C) 
• Chronic progressive external ophthalmoplegia (CPEO) 
(m.3243A>G, m.4274T>C) 
• Myopathy (m.14709T>C, m.12320A>G) 
• Cardiomyopathy (m.3243A>G, m.4269A>G) 
• Diabetes and deafness (m.3243A>G, m.12258C>A) 
• Encephalomyopathy (m.1606G>A, m.10010T>C) 
• Nonsyndromic sensorineural deafness (m.7445A>G) 
Point mutation in rRNA 
genes 
• Aminoglycoside-induced nonsyndromic deafness 
(m.1555A>G) 
Rearrangements 
(deletions & duplications) 
• Chronic progressive external ophthalmoplegia (CPEO) 
• Kearns-Sayre syndrome (KSS) 
• Diabetes and deafness 
 
Despite the multitude of pathogenic mutations, clinical manifestations of mitochondrial 
disease are often very similar. In general, clinical manifestations occur in tissues and organs 
which are heavily dependent on the respiratory chain due to their high metabolic demands, 
such as the brain, muscle and heart. Neurological phenotypes and muscular phenotype such as 
myopathy have significant morbidity in this disease group, however cardiac, ophthalmic and 
endocrine systems are also frequently involved [41]. As discussed, the mtDNA mutations can 
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be homoplasmic or heteroplasmic and therefore the severity of the mitochondrial defects is 
influenced by the degree of heteroplasmy. 
 
The germ-line transmission of mutated mtDNA is by the maternal lineage. The amount of 
mutated mtDNA transmitted to the offspring is variable and is determined by the “genetic 
bottleneck” [42]. This concept was originally illustrated in the maternal lineage of Holstein 
cows in 1980 [43], however the mechanisms remain unclear. The egg cell contains a high 
number of mitochondria, with the possibility that some of the mtDNA molecules are mutated. 
During early oogenesis, the number of mtDNA molecules is greatly reduced and a number are 
selectively transferred into each oocyte. Depending on the degree of heteroplasmy of the egg, 
a random shift of mtDNA mutational load of the embryo is determined [44]. Similar to 
sporadic mutations, a single mtDNA molecule can mutate during mitoses of early oogenesis 
or embryogenesis and depending on the time and the affected cell, this event leads to the 
distribution of a different degree of heteroplasmy across the somatic cells and subsequent 
dysfunction of the affected organs or tissues. The type of the affected cells in the early stages 
of development result in the mosaic-like distribution in the histomorphology. 
 
In most mtDNA-associated mitochondrial diseases, such as CPEO, MELAS and MERRF, 
skeletal muscle shows a pathological mosaicism of metabolically compensated and 
noncompensated fibers. The mosaic is apparent using histochemical stains, typically with 
combined cytochrome c oxidase/succinate dehydrogenase (COX/SDH) staining. This is a 
common diagnostic test, whereby decompensated fibers are negative for the activity of 
complex IV of the respiratory chain, cytochrome c oxidase (COX-) but retain the blue (SDH) 
stain, which reflects the activity of the nuclear-encoded complex II of the respiratory chain 
(succinate–ubiquinone oxidoreductase). As discussed, complex II is the only respiratory 
complex entirely encoded by nuclear DNA, therefore the SDH stain is unaffected by 
deleterious mutations of mtDNA and is thus a reliable marker of mitochondrial abundance. 
Compensated fibers stain orange as a result of a functioning complex IV. 
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It is clear that the level of mutated mtDNA can alter over the course of a lifetime. A 
mathematical model of human mtDNA replication, "relaxed replication of mtDNA”, provides 
an explanation for the late-onset of some mitochondrial diseases [45]. The model describes 
that changes of the proportion of mutant mtDNA in post-mitotic tissues are due to the 
different rates between the replication of mutant mtDNA and of wild-type (wt) mtDNA, 
which can subsequently affect the threshold of mutant copies. For instance, mtDNA with 
large-scale deletions could have an advantage on repopulating cells over wt mtDNA. Another 
process termed "mitotic segregation" might explain the change in mitotic tissue. In a 
heteroplasmic state, the cell randomly transmits the mutated and non-mutated mitochondria 
between the daughter cells [46]. Therefore, mutation load is variable from one cell generation 
to the next, which will result in a mutational load at or below the pathogenic threshold over 
time. The clinical syndromes associated with mtDNA mutations are therefore extremely 
variable in presentation and can occur at any age. 
 
1.3.3 Pathophysiological effects of mtDNA mutations 
 
The expression of mtDNA is indispensable for mitochondrial oxidative phosphorylation 
(OXPHOS), therefore, the primary response to mtDNA mutations is the decline of cellular 
energy production. A large number of pathogenic mtDNA variants detrimentally influence the 
activity of electron transport chain and ATP synthesis. Furthermore, mutations of mtDNA 
have several adverse effects on mitochondrial dynamics and induce inflammasome activation 
to disrupt the mitochondrial homeostasis and inflammatory response. 
 
Mitochondria are dynamic reticular organelles with high plasticity of structures, as they 
undergo constant fission and fusion. These dynamic processes regulate mitochondrial 
homeostasis and maintain mitochondrial function by segregating the destroyed mitochondria 
via the fission process and facilitating mitochondrial remodeling, rearrangement and 
proliferation via the fusion process [47, 48]. Consequently, mitochondria can respond rapidly 
to cellular energy demands, whether adapting to the physiological or environmental changes.  
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In mammalian cells, mitochondrial fusion is mediated by the fusion relevant proteins 
mitofusin 1 (Mfn1) and 2 (Mfn2) as well as optic atrophy protein 1 (OPA1) (Figure 1.3A). 
Mfn1, Mfn2 and OPA1 are dynamin-related GTPases responsible for the mitochondrial fusion 
process of the outer and inner mitochondrial membranes, respectively. Meanwhile, a fraction 
of Mfn2 is also found in the endoplasmic reticulum (ER), regulating ER morphology, 
bridging mitochondria and ER, and facilitating mitochondrial uptake of calcium from ER 
stores [49]. OPA1 is necessary to retain mitochondrial genomes and control apoptosis, while, 
downregulation of OPA1 can result in aberrant cristae remodeling and the release of 
cytochrome c [50-53]. Mutations in Mfn2 and OPA1 have been reported in patients with 
multisystem clinical symptoms, including progressive external ophthalmoplegia and 
autosomal dominant optic atrophy (ADOA), with mtDNA large deletions in skeletal muscle 
[54-56]. Moreover, it has been confirmed by the study in yeast that fusion deficient mutants 
show defects of the respiration chain and failure to maintain the mitochondrial genome [57, 
58]. 
 
Fission is mediated by another cytosolic GTPase, dynamin-related protein 1 (Drp1), which 
tethers to the fission proteins (such as hFis1) anchored in the mitochondrial outer membrane 
(Figure 1.3B) [59]. Fission is directly correlated with efficient mitochondrial transport and 
apoptosis. A number of studies show that mitochondrial fragmentation leads to apoptosis 
through the Drp1-dependent pathway in many organisms. Additionally, Bax, a pro-apoptotic 
Bcl-2 family member, interacts with Mfn1, Mfn2 and Drp1, providing support for the 
association between apoptosis and mitochondrial dynamics [60, 61]. Waterham et al. reported 
a mutation in the Drp1 gene resulting in abnormal brain development and lethality due to the 
fission defect [62]. Furthermore, Lipton reported that S-nitrosylated Drp1 (SNO-Drp1) 
affected amyloid-β (Aβ)-induced excessive mitochondrial fission and contributed to neuronal 
death and synaptic loss [63]. 
 
 24 
 
 
Inflammasomes are cytosolic multiprotein complexes formed in response to pathogenic 
microbes and physiological stimuli to activate proinflammatory caspases such as caspase-1, 
facilitating the maturation and secretion of interleukin-1β (IL-1β) and IL-18 [64]. The 
essential components of the inflammasome complexes contain nucleotide-binding domain and 
leucine-rich repeat containing proteins 1 (NLRP1), NLRP3 and NLRC4, which belong to the 
NOD-like receptor (NLR) family, and the effector molecule caspase-1, as well as the 
apoptosis-associated speck-like adaptor protein (ASC). NLRP3 is the most intensively studied 
component of the inflammasome complex and integrates with the adaptor ASC protein and 
procaspase-1 to form the NLRP3 complex. It is reported that NLRP3 inflammasomes produce 
mature IL-1β in the presence of signal 1 (often NF-κB) owing to activation caused by 
mitochondrial apoptotic signaling [65]. Aggregated β-amyloid and extracellular ATP can also 
Figure	1.3:	Mitochondrial	fusion	and	fission	in	mammalian	cells.	(A)	Mitochondrial	fusion	
requires	dynamin-related	GTPase	proteins	Mfn1	and	Mfn2,	located	in	the	outer	mitochondria	
membrane	(OMM),	in	addition	to	OPA1,	located	in	the	inner	mitochondria	membrane	(IMM).	
(B)	Mitochondrial	fission	is	mediated	by	cytosolic	dynamin-related	protein	1	(Drp1).	Drp1	is	
also	a	GTPase	protein,	which	tethers	to	four	fission	proteins	(Mff,	Fis1,	MID49,	MID51)	
anchored	in	the	OMM.	
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activate the NLRP3 inflammasome and additionally induce mitochondrial apoptosis and 
damage leading to the release of oxidized mtDNA into the cytoplasm [66]. Furthermore, 
Shimada et al. reported oxidized mtDNA, which was generated and released into the 
cytoplasm due to ROS production and K+ efflux, to serve as a NLRP3 direct activator to 
drive inflammasome assembly [65]. It remains unclear how exactly the oxidized mtDNA 
triggers the NLPR3 inflammasome, but it is speculated that the Ca2+ signaling maybe act as 
an intermediate step to promote the activation of NLPR3 complex [67]. 
 
1.3.4 Defense mechanisms against mtDNA mutations 
 
Mitochondrial quality control is crucial to maintain mitochondrial function and cellular 
homeostasis [68-70]. During aging, mitochondrial and nuclear genomes accumulate mutations 
that impair the mitochondria. Mitochondrial quality control therefore removes the 
dysfunctional mitochondria and prevents the onset of mitochondrial disease. 
 
Primary mechanisms for mitochondrial quality control are three-fold and relate to the removal 
of the damaged proteins or of the damaged organelle. The first mechanism is concerned with 
the core process for damaged protein degradation within mitochondria which hinges on the 
ubiquitin–proteasome system (UPS). As the energy factories of the cell, mitochondria are 
exposed to high levels of ROS production which can damage protein structure and affect 
protein folding. The mitochondrial unfolded protein response (UPRmt) is triggered by the 
accumulation of unfolded or misfolded proteins in the mitochondria leading to elevation of 
mitochondrial chaperone proteins (such as chaperonin heat shock protein 60 (HSP60) and 
HSP70) and proteases (such as ClpP), which ensure the proper folding of misfolded proteins 
or mediate damaged protein degradation, respectively [71]. UPS can eliminate misfolded, 
oxidized or denatured mitochondrial proteins embedded in the outer mitochondrial membrane 
[72]. The second mechanism is concerned with mitochondrial morphology and dynamic 
fission-fusion events to compensate for damaged mitochondria at the organelle level as the 
mitochondria are constantly fragmenting and fusing with a steadily regulated manner [57, 73] . 
The third mechanism concerns removal of the damaged organelles by a process of autophagy, 
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more precisely termed mitophagy in the setting of the mitochondria. In mitophagy, when 
mitochondrial defects reach the damage threshold, the process of fusion becomes blocked and 
the mitochondrion as a whole is eliminated via selective autophagy [74]. The term autophagy 
is defined as the degradation of cytosolic components and organelles within lysosomes [75]. 
Recent studies have indicated that the interplay between mitochondrial autophagy with the 
mitochondrial function is a responsible mechanism underlying neurodegenerative disease. As 
mitophagy is a major mitochondrial quality control mechanism, playing an important role in 
cellular adaption to oxidative stress, it is not surprising that dysregulation of mitophagy is 
relevant to neurodegenerative diseases, which in turn are associated with mitochondrial 
dysfunction caused by mtDNA mutations [76]. Mitophagy deficiencies lead to the 
accumulation of dysfunctional mitochondria, promoting excessive ROS generation and 
cytosolic transmission of mtDNA, resulting in inflammatory activation [77]. 
 
1.4 Mitochondrial proteomics 
 
Proteomics is a high-throughput and large-scale method for identification and quantification 
of proteins within a biological unit such a cells, tissues or organisms, providing a link between 
genotype and phenotype. The first study of mitochondrial proteomics was described in 1998 
[78]. Over the last 20 years, the human mitochondrial proteome has been mapped and defined, 
detecting more than 1,000 mitochondrial proteins encoded by both the mitochondrial genome 
and the nuclear genome [79]. Since the mitochondria participate in a plethora of pathological 
and physiological processes, the investigation of alterations of the mitochondrial proteome is 
beneficial to clarify the pathogenic mechanisms of numerous human diseases. At present, the 
focus of mitochondrial proteomics research is on the verification of all of the mitochondrial 
protein components within a single sample and their post-translational modifications (PTMs) 
in order to develop an integrated mitochondrial proteome database.  In addition, the study of 
comparative mitochondrial proteomics aims to explore the differentially expressed 
mitochondrial proteins in abnormal samples or under special states in favor of revealing the 
pathogenesis of mitochondrial diseases. 
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Mitochondrial proteomics has been a “hot topic” for the past decade, as mitochondria 
represent a hub of cellular signaling activity and pathways involved in disease pathogenic 
mechanisms associated with a wide disease spectrum [68, 80-82] and with the physiological 
aging process [83, 84]. There is however only limited availability of sufficient samples from 
human tissues for proteome analyses due to strict medical and ethical issues. The continuous 
development in the methods of sample preparation and sensitivity and accuracy of mass 
spectrometry analysis techniques however allows examination of small, more readily 
available biopsy samples to be realized. This produces valuable information on pathology 
through direct proteomics analysis of affected disease-associated material. 
 
1.4.1 Techniques for mitochondrial proteomics 
 
The identification of differential proteomics is most frequently accomplished by two-
dimensional gel electrophoresis (2DE) and mass spectrometry (MS). For studies of 
mitochondrial proteomics, the most direct technique is to identify mitochondrial proteins in 
purified fractions of mitochondria from samples by MS. 2DE-based proteomic analysis is 
however unable to visualize low-abundant proteins, owing to the difficulty in 
separating hydrophobic proteins and proteins with the extreme isoelectric point or molecular 
weights, such as membrane proteins [85]. To date, methods have been explored to perform the 
separation of hydrophobic proteins, including transmembrane domain (TM) proteins, such 
as sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), 
benzyldimethyln-hexadecylammonium chloride (16-BAC)/SDS-PAGE and cetyl 
trimethylammonium bromide (CTAB)/SDS-PAGE [86]. With the development of 
electrospray ionisation (ESI), liquid chromatography coupled with MS (LC-MS) arose as a 
powerful technique with high sensitivity and specificity which facilitates protein 
quantification using stable isotope labeling (in vitro and in vivo), as well as avoiding the 
limitation of low dynamic range due to gel staining. Quantitative proteomic analyses can be 
accomplished through gel-free isotope labeling approaches such as isotope-coded affinity tags 
(ICATs) [87], stable isotope labeling with amino acids in cell culture (SILAC) [88], isobaric 
tags for relative and absolute quantitation (iTRAQ) [89] and enzymatically with 18O during 
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proteolytic digestion, for accurate determination of the amount of each protein [90]. MS-
based quantitative proteomics has the capability to incorporate large amounts of phenotypic 
information in relation to protein expression, interactions and post-translational modifications 
[91]. 
 
Liquid chromatography-mass spectrometry (LC-MS) instruments now enable the 
identification of proteins and peptides at extremely low levels. The completion of such 
“microproteomics” relies on a modified technique for microgram-quantities of sample and on 
effective sample processing. Thus, sample size and complexity should be given more 
attention in LC-MS. MS analysis should preferably be carried out in affected tissues such as 
skeletal muscle, a predominant target tissue in mitochondrial disease [92]. However, since the 
vast majority of muscle mass consists of large and highly abundant sarcomeric proteins, 
skeletal muscle is technically challenging for mass spectrometry [93]. Laser capture 
microdissection (LCM) is a useful technique that allows for pure isolation of the cells of 
interest or anatomical regions of tissue from sample sections [94, 95]. Banded with 
immunohistochemistry, LCM can remove targeted cell types according to a specific 
histological stain or protein marker, thus cells of interest can be extracted and identified 
without the interference of adjacent tissue structures. The verification of peptide–spectrum 
assignments should be checked carefully. Software tools available to automatically analyze 
the tandem mass spectrometry datasets include Trans-Proteomic pipeline (TPP), Census™ [96] 
and MaxQuant™ [97]. 
 
1.4.2 Applications of mitochondrial proteomics 
 
Mitochondrial proteomics have been widely applied to illuminate molecular alterations 
responsible for the pathogenesis of mitochondrial diseases at the protein level through large 
scale proteomics analyses. The identification of mitochondrial disease-causing proteins 
contributes not only to the comprehension of molecular signaling pathways associated with 
mitochondrial and mitochondrial-related diseases but also to the discovery of potential 
therapeutic targets. Considering that most mitochondrial proteins are encoded by nDNA and 
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not the mtDNA, the study of mitochondrial mechanisms should make an alliance between 
proteomic and genomic data. Rabilloud et al. applied comparative proteomics to describe the 
effects of mutations in mitochondrial tRNA genes on the steady-state level of mitochondrial 
protein encoded by nDNA [98]. A similar proteomic approach was used to compare wild-type 
with MERRF mitochondria from sibling human cybrid cell lines and performed a quantitative 
analysis [99]. Furthermore, a study performing quantitative mitochondrial proteomics showed 
that acyl-CoA dehydrogenase short chain (ACADS) deficiency had a widespread influence on 
fatty acid beta-oxidation [100]. Taking all of the above factors into account, mitochondrial 
proteomics will beyond doubt supply useful information for various mitochondrial related 
studies. 
 
As mentioned in 1.3.2, pathological mtDNA mutation mosaicism is superimposed onto the 
physiological mosaicism of different fiber types which characterizes skeletal muscle, one 
slow-type 1 and two fast-type 2 (2A and 2X, three in rodents which also have 2B fibers), each 
with specific contractile and metabolic properties. In humans, slow fibers have more abundant 
mitochondria than fast fibers. Using MS-based proteomics, related study has previously 
shown that human fast and slow fibers undergo different changes during the process of aging 
[101]. 
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2. Objective 
 
This study utilizes the combination of laser capture microdissection (LCM) and quantitative 
proteomics to investigate novel pathogenic mechanisms of mitochondrial diseases at the level 
of individual muscle fibers. The mosaicism of COX+ and COX- fibers in mtDNA-related 
diseases provides a unique opportunity to reveal mitochondrial disease mechanisms at the 
cellular level. Based on this objective, a LCM-based proteomic workflow is performed to 
excise the pure cells of COX+ and COX- fibers from frozen muscle biopsies of CPEO 
patients, followed by a rapid and deep proteome analysis. Since LCM enables microsampling, 
our LCM-based proteomic workflow requires only little tissue, in the ng range, to yield 
quantitative data on thousands of proteins. Comprehensive knowledge of proteomic analyses 
in individual COX+ and COX- fibers can illuminate the pathogenesis of mitochondrial 
disease and reveal the fiber type-specific adaptive molecular responses to mitochondrial 
dysfunction. 
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3. Materials and Methods 
 
3.1 Ethical Statement 
 
The research project was approved by the ethics committee of the LMU Munich and the study 
has been performed in accordance with the ethical standards laid down in the 1964 
Declaration of Helsinki and its subsequent amendments. Muscle biopsies were obtained for 
diagnostic purposes and written informed consent for using parts of it for research purposes 
was obtained from patients or their legal guardians. 
 
3.2 Patients 
 
All muscle specimens and myoblast cells were obtained from the biobank of the German 
network for mitochondrial diseases (mitoNET) at the Friedrich-Baur-Institute. We randomly 
selected 3 patients with CPEO, defined by the pathognomonic clinical phenotype of the 
presence of ragged red fibers (RRF) on muscle biopsy and the detection of an mtDNA 
deletion (Table 3.1). Patient 1 is a male German patient who developed ptosis and 
progressive external opthalmoplegia (PEO) with double vision from the age of 16. From the 
age of 39, he complained of mild muscle weakness of the upper and lower extremities. The 
diagnosis of CPEO was confirmed by muscle biopsy showing RRF and COX- fibers in 
addition to a 5 kb mtDNA single deletion (common deletion) in 50% of mtDNA molecules. 
Patient 2 is a female Turkish patient who developed ptosis and PEO from the age of 20. From 
the age of 32, she complained of mild muscle pain and weakness of the upper and lower 
extremities. The diagnosis of CPEO was confirmed by muscle biopsy showing RRF and 
COX- fibers in addition to a 6 kb mtDNA single deletion in 50% of mtDNA molecules. 
Patient 3 is a male German patient who developed ptosis and PEO with double vision from 
the age of 34. He did not suffer from muscle weakness of the upper and lower extremities. 
The diagnosis of CPEO was confirmed by muscle biopsy showing RRF and COX- fibers in 
addition to a 5 kb mtDNA single deletion (common deletion) in 50% of mtDNA molecules.  
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Diagnostic fragments of the right deltoid or left quadriceps muscle were collected by open 
muscle biopsy. Muscle specimens were then immediately frozen in liquid nitrogen and stored 
at -80°C. The control myoblast cells were randomly selected from 3 patients with no known 
mitochondrial disease. 
 
Table 3.1: Basic characteristics of the study participants. 
CPEO Race Sex 
Age at biopsy 
(yrs) 
Size / heteroplasmy 
of single mtDNA 
deletion 
Phenotype 
Patient 1 
European-
Caucasian 
Male 38 5 kb / 50% CPEO 
Patient 2 
European-
Caucasian 
Female 32 6 kb / 50% CPEO 
Patient 3 
European-
Caucasian 
Male 49 5 kb / 50% CPEO 
 
 
3.3 Histochemistry 
 
3.3.1 Tissue preparation for cryosectioning 
 
Muscle specimens were transferred in liquid nitrogen to the cryostat. Alternate serial sections 
(10 µm) were adhered to Superfrost plus microscope slides for histochemical staining and to 
membrane slides for laser microdissection. Superfrost plus slides were air-dried for ~24h and 
then stored at -20°C for the next histochemical staining. Membrane slides were stored at -
80°C prior to cutting and processing for MS-based proteomics. 
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Table 3.2: Consumables and equipment for tissue preparation 
Consumables / equipment Product number Manufacturer 
Leica Membrane Slides © 
PEN membrane 2.0μm 
11505158 
Micro Dissect Gmbh 
(Herborn) 
Slides superfrost 7201277 Menzel GmbH + Co KG 
Coverslips 190002450 IDL (Nidderau) 
Cryostat 2800 Frigocut E — Reichert-Jung 
 
 
3.3.2 Sequential cytochrome c oxidase / succinate dehydrogenase (COX/SDH) 
histochemistry 
 
Slides were allowed to thaw and dry at room temperature for 1h and were processed 
according to standard protocols [102]. For COX staining, sections were incubated in 
cytochrome c oxidase medium (100 μM cytochrome c, 4 mM diaminobenzidine 
tetrahydrochloride, and 20 μg/ml catalase in 0.2 M phosphate buffer, pH 7.0) for 90 min at 
37 °C. Sections were then washed in standard PBS, pH 7.4 (2 × 5 min) and incubated in 
succinate dehydrogenase (SDH) medium (130 mM sodium succinate, 200 μM phenazine 
methosulphate, 1 mM sodium azide, 1.5 mM nitroblue tetrazolium in 0.2 M phosphate buffer) 
for 120 min at 37 °C. Sections were then washed in PBS, pH 7.4 (2 × 5 min) and in double-
distilled water (2 × 2 min) rinsed in distilled and dehydrated in an increasing ethanol series up 
to 100%, prior to incubation in xylene and mounting in Eukitt (Table 3.3 and 3.4). 
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Table 3.3: Chemicals for COX-SDH staining 
Chemicals Product Number Manufacturer 
Diaminobenzidine (DAB) D-5637 Sigma 
Cytochrome c C-2506 Sigma 
Sodium succinate S-2378 Sigma 
Nitro blue tetrazolium (NBT) N-6876 Sigma 
Phenazine methosulfate P-9625 Sigma 
Sodium azide BDH30111 Sigma 
Catalase C-9322 Sigma 
PBS 
P0014 (0.2M, Ph7.5) 
P0008 (0.1M, Ph7.4) 
Sigma-Aldrich 
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Table 3.4: Protocols for combined COX-SDH staining. 
Preparations of samples 
 1. Thaw and dry at room temperatures for 1h 
COX staining 
 
2. 30mg cytochrome c, 30mg diaminobenzidine 
tetrahydrochloride add to 30ml 0.1M PBS 
3. Adjust PH to 7.0 
4. Add 20mg catalase to CCO solution 
5. Incubate at 37 ° C for 90 mins 
Wash 
 6. 5 mins in 0.2M PBS for 2 times 
SDH staining 
 
7. 6,12mg PMS add to 10ml 0,1M phosphate buffer, devide 
3ml aliquots and store at -20 ° C 
8. Make 0.2M Na-succinate solutions by mixing 2710mg 
sodium succinate with 50ml double-distilled water 
9. 15ml 0.2M sodium succinate solutions, 40mg NBT add 
to15 ml 0.2M PBS 
10. Incubate at 37 ° C for 120 mins 
Wash 
 
11. 5 mins in 0.2M PBS for 2 times 
12. 2 mins in double-distilled water for 2 times 
Decolorizer 
 
14. Wash 30 secs in 75% alcohol 
15. Wash 30 secs in 95% alcohol 
16. Wash 30 secs in 99% alcohol for 2 times 
Storage 
 18. Cover medium and coverslip 
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3.4 Laser capture microdissection (LCM) 
 
In LCM, polyethylene naphthalate (PEN) membranes are necessary. These special 
microscope slides are coated with a thin transparent film on the surface of the glass slide that 
can be cut off by a weak laser beam [103]. By cutting off the marked area of the tissue, the 
cells of interest fall down and are collected in a prepared reaction vessel. The primary 
advantage of this membrane slide is that the PEN membrane provides great consistency in the 
process of capturing and collecting cells, which can ensure not only faster collection of large 
sections of samples but also less dependency on dehydration contributing to the complete 
removal of the sample from the slide. 
 
Table 3.5: Consumables and laser capture microdissection device 
Chemicals Product Number Manufacturer 
PEN membrane slides 11505158 Leica 
Leica LMD 7000 system — Leica 
0.5ml Thermo-Tube AB-0350 Thermo Scientific 
 
 
The procedure was essentially carried out as described in the literature by Koob et al. [104]. 
The images of whole COX/SDH stained slides and sections of interest were acquired and 
stored using a Leica LMD 7000 System. Next, we observed the unstained serial sections 
under the microscope at various magnifications and compared with the pictures of stained 
sections individually. According to the recognizable histochemical features of COX+ and 
COX- cells, we determined the coordinates of their corresponding unstained cells and cut 
them by LCM. 100 COX+ and 100 COX- cells were collected for each patient. Similarly, we 
selected 3 COX+ and 3 COX- single fibers with clearly recognizable histochemical features 
for each patient, then obtained 20 COX+ or 20 COX- serial sections for each fiber separately. 
The whole procedure was precisely timed for each sample and carried out in less than 30 min 
at room temperature. Fiber sections were captured by cutting the region of interest onto the 
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caps of 0.5ml Thermo-Tube, which were carefully closed and immediately frozen in liquid 
nitrogen at the end of the procedure. Samples were stored at -80°C until used. 
 
3.5 Sample preparation and high pH-reversed phase fractionation 
 
Total muscle (62 mg) was crushed in liquid nitrogen using a pestle and mortar. Powdered 
muscle samples and myoblast cells (3x 106 cells) were resuspended in 310 µl (5 µl/mg) and 
200 µl SDC reduction and alkylation buffer, respectively. Samples were further boiled for 10 
minutes to denature proteins [105]. The total muscle sample was further mixed (six times 30 
seconds and cooled on ice in between) using a FastPrep®-24 Instrument (MP Biomedicals). 
Protein concentration was measured using the Tryptophan assay and 250 µg were digested 
overnight with Lys-C and trypsin in a 1:25 ratio (µg of enzyme to µg of protein) at 37 oC, 
under continuous stirring at 1700 rpm. On the following day, samples were sonicated using a 
Bioruptor (Diagenode, 15 cycles of 30 sec) and further digested for 3 hours with Lys-C and 
trypsin (1:100 ratio). Peptides were acidified to a final concentration of 0.1% trifluoroacetic 
acid (TFA) for SDB-RPS (Polystyrene-divinylbenzene copolymer partially modified with 
sulfonic acid) binding and 40 µg of peptides were loaded on four 14-gauge Stage-Tip plugs 
(Figure 3.1). Peptides were washed first with isopropanol / 1%TFA (200 µl) and then 0.2% 
TFA (200 µl) using an in-house Stage-Tip centrifuge at 2000 x g. Peptides were eluted with 
60 µl of elution buffer (80% acetonitrile / 1% ammonia) into auto sampler vials and dried at 
60 C using a SpeedVac centrifuge (Eppendorf, Concentrator plus). Peptides were resuspended 
in 2% acetonitrile / 0.1% TFA and sonicated (Branson Ultrasonics, Ultrasonics Cleaner 
Model 2510) before peptide concentration estimation using the Nanodrop. About 40 µg of 
peptides of each sample were further fractionated into 54 fractions by the Spider fractionator 
device, which is under commercial development by PreOmics GmbH, Martinsried, Germany, 
with a rotor valve shift of 90 s and concatenated into 16 fractions using high pH reversed-
phase fractionation, as previously described [106]. 
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Table 3.6 Buffers used for iST 
Lysis buffer 
1% (w/v) SDC, 10mM TCEP, 40mM CAA, 100mM Tris 
pH8.5 
Dilution buffer milliQ Water (LysC - 1:10, Trypsin - 1:10, Lysate : Buffer) 
Loading buffer (SDB-RPS) 50% (v/v) Ethyl acetate, 0.5% (v/v) TFA (1:2) 
Washing buffer (SDB-RPS) 
1. 50 µl 100% (v/v) Ethyl acetate, 50 µl 0.2% (v/v) TFA 
2. 100 µl 0.2% (v/v) TFA 
 
 
3.6 Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) analysis 
 
Nanoflow LC-MS/MS analysis of tryptic peptides was conducted on a Q Exactive HF 
Orbitrap (Thermo Fisher Scientific) coupled to an EASYnLC 1200 ultra-high-pressure system 
(Thermo Fisher Scientific) via a nano-electrospray ion source (Thermo Fisher Scientific). 
Peptides were loaded on a 50 cm HPLC-column (75 μm inner diameter; in-house packed 
Figure	3.1:	Protocol	of	minimal	 sample-processing	 completed	 in	an	enclosed	volume	
[108].	 (a)	 Profile	 of	 the	 in-StageTip	 (iST)	 sample-processing	method.	 Protein	material	 are	
directly	 transferred	 into	 a	 StageTip	 and	 are	 processed	 in	 three	 steps.	 (b)	 Enclosed	 iST	
reactor.	 (c)	 96-well	 iST	device	 for	 sample	processing.	 Inset,	 shows	 StageTips	 reaching	 into	
PCR	tubes.	
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using ReproSil-Pur C18-AQ 1.9 µm silica beads; Dr. Maisch). Peptides were separated using 
a linear gradient from 2% B to 20% B in 55 minutes and stepped up to 40% in 40 minutes 
followed by a 5 minute wash at 98% B at 350 nl/min where solvent A was 0.1% formic acid 
in water and solvent B was 80% acetonitrile and 0.1% formic acid in water. The gradient was 
followed by a 5 min 98% B wash and the total duration of the run was 100 minutes. Column 
temperature was kept at 60 C by a Peltier element-containing, in-house developed oven. 
 
The mass spectrometer was operated in “top-15” data-dependent mode, collecting MS spectra 
in the orbitrap mass analyzer (60,000 resolution, 300-1,650 m/z range) with an automatic gain 
control (AGC) target of 3E6 and a maximum ion injection time of 25 ms. The most intense 
ions from the full scan were isolated with an isolation width of 1.5 m/z. Following higher-
energy collisional dissociation (HCD), MS/MS spectra were collected in the orbitrap (15,000 
resolution) with an AGC target of 5E4 and a maximum ion injection time of 60 ms. Precursor 
dynamic exclusion was enabled with a duration of 30 seconds. 
 
3.7 Computational proteomics 
 
The MaxQuant software (version 1.5.4.3) was used for the analysis of raw files. Peak lists 
were searched against the human UniProt FASTA reference proteomes version of 2016 as 
well as against a common contaminants database using the Andromeda search engine [97, 
107]. Carbamidomethyl was included in the search as a fixed modification, oxidation (M) and 
phospho (STY) as variable modifications. The FDR was set to 1% for both peptides 
(minimum length of 7 amino acids) and proteins and was calculated by searching a reverse 
database. Peptide identification was performed with an initial allowed precursor mass 
deviation up to 7 ppm and an allowed fragment mass deviation 20 ppm. For the relative 
quantification of MYH isoforms, only peptides unique to each isoform were used for protein 
quantification in MaxQuant. The relative expression of each MYH isoform is calculated as 
percent of the summed intensity of the four adult isoforms (MYH1, MYH2, MYH4, MYH7). 
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3.8 Bioinformatic and statistical analysis 
 
The Perseus software (version 1.5.4.2), part of the MaxQuant environment [108] was used for 
data analysis and statistical analysis. Categorical annotations were provided in the form of 
UniProt Keywords, KEGG and Gene Ontology. Mitocarta2 scores were provided as 
numerical annotations and filtered for x>1. Label free quantification (MaxLFQ) was used for 
protein quantification in all experiments, using a Z score where indicated [109]. Student’s T-
test was performed using a p value of 0.05 for truncation. Normalization for mitochondrial 
content was performed by dividing expression values by the expression of citrate synthase. 
PCA and cluster analysis was performed in the Perseus software using logged expression 
values. Where indicated, missing values were imputed by using random numbers from a 
normal distribution to simulate the expression of low abundant proteins. We used a width 
parameter of 0.3 of the standard deviation of all values in the dataset with a down shift by 1.8 
times this standard deviation. These parameters were empirically determined over many 
different proteomics data sets. 
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4. Results 
 
4.1 Combining laser capture microdissection (LCM) and proteomics to study 
mechanisms of mitochondrial disorders  
 
We performed a LCM-based quantitative proteomic analysis approach for mitochondrial 
proteins that contribute to the pathogenesis of mitochondrial disorders. This LCM-based 
proteomic work flow consists of four major steps (Figure 4.1). The first step is to harvest 
COX+ and COX- cells from frozen muscle tissue specimens. The LCM allows for a more 
precise collection of interesting cells not only in the whole muscle samples but also in the 
single muscle fiber. The second step involves samples preparation by the in-StageTip method 
[105], which allows sample processing in a single reaction vessel to minimize sample loss, 
contamination, handling time and to increase quantification accuracy.  The third step contains 
the measurement of high sensitivity, sequencing speed, and mass accuracy using a quadrupole 
- Orbitrap mass spectrometer (QExactive HF), and rapid qualitation, quantitation and 
statistical analysis of multiple proteins[110]. For the identification of proteins with low 
expression, we first built a fixed resource consisting of deep human skeletal muscle 
proteomes as libraries of identified peptide features by single-shot MS analyses of 
individually excised 10 µm sections of the frozen muscle biopsies. Based on the “match 
between runs” feature of the MaxQuant analysis software [97, 111], we transferred 
identifications from the peptide libraries to the patients’ samples[93]. The last step involves 
the comparative analysis between different samples to detect molecular markers or pathways 
which are associated with mechanisms of initiation and progression of mitochondrial diseases. 
A flow chart summarizing the LCM-based proteomic strategy is shown in Fig 4.1. 
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Figure	4.1:	Outline	of	the	LCM-based	proteomic	strategy	to	investigate	mitochondrial	
diseases.	
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With our LCM-based proteomic strategy, triplicate proteome analyses of muscle sections 
from one patient can be carried out in 6 hours of total machine time and yield quantification 
of over 4000 proteins (Figure 4.1.2 and 4.1.3). The same strategy allowed the proteomic 
analysis of serial sections of single fibers, in which we quantified 2440 +/- 350 proteins on 
average (Figure 4.1.3). 
 
Our library-based strategy triplicated protein identification with respect to direct sequencing 
by tandem mass spectrometry (MSMS). The advantage of this method was proportionally 
stronger in the dataset obtained by LCM of single muscle fibers, where peptides from low 
abundant proteins presumably fall below the intensity limit for identification by MSMS 
(Figure 4.1.2). The identification of proteins reached to 65% coverage of mitochondrial 
annotations according to our deep skeletal muscle libraries. Most of mitochondrial functional 
proteins, like proteins related with the respiratory chain and tricarboxylic acid (TCA) cycle, 
were mostly identified by MSMS.  
 
 
 
Figure	4.1.2:	Number	of	proteins	quantified	for	whole	muscle	samples	of	each	patient.	
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Figure	4.1.3:	Number	of	proteins	quantified	for	single	muscle	fibers	of	each	patient.	
 
4.2  LCM capture of skeletal muscle sections 
 
In this study, we used frozen skeletal muscle biopsies of CPEO patients, in which a 
histochemical activity for COX/SDH staining showed a mosaic of brown (COX positive) and 
blue (COX negative) fibers (Figure 4.2.1A). Given the cellular histological distribution, LCM 
was used as a means to capture COX+ and COX- cells separately. Figure 4.2.1 shows pre- 
and post-microdissected tissue images and captured muscle cells. The infrared capture laser 
was applied to be as a microdissection instrument instead of the ultraviolet (UV) cutting laser, 
since the thermal energy provided by UV-laser approach could generate potential harm and 
lower protein harvest yields of interesting cells when cutting small cells or tissue 
fragments[112].  
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It is necessary that the sections of PEN membrane slides are exposed to very short air drying 
at room temperature to ensure a consistent and smooth cellular microdissection by LCM. 
Otherwise, excessive air drying or external moisture of sections would adversely impact on 
the separation of the plastic film from the glass slide. After the capture microdissection of 
individual fibers from 10 µm sections by LCM, we obtained separate pools of 100 COX+ and 
100 COX- fibers from each of three CPEO patients. Using pools of muscle fiber sections 
helped to avoid sampling biases, such as different fiber type composition leading to different 
mitochondrial content. Besides, 20 COX+ and 20 COX- serial sections were cut in each fiber 
of selected 3 COX+ and 3 COX- single fibers for one patient separately.  
 
 
 
 
Figure	4.2.1:	The	processes	of	LCM	for	a	
skeletal	muscle	section.	A,	B:	Through	the	
comparison	between	stained	section	A	and	
unstained	section	B	under	the	microscope,	the	
COX-deficient	cell	(black	arrow)	is	marked	and	
excised	by	laser	microdissection.	C:	This	trapped	
cell	is	collected	in	the	cap	of	the	reaction	tube	
after	LCM.	
A 
C 
B 
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4.3 Expression of respiratory complexes in COX+ and COX- muscle fibers 
 
In this study, we quantified 73 out of 95 proteins annotated to the respiratory chain complexes 
and ATP synthase in humans (GO annotation). Then we differentiated the subunits of the 
respiratory chain complexes according to their gene localization in mtDNA (Figure 4.3.1, red 
boxes) and nDNA (Figure 4.3.1, black boxes), respectively, and analysed their differences in 
COX- and COX+ fiber pools.  
 
For COX complex IV, all subunits showed more abundant in COX+ fibers compared to COX- 
fibers (Figure 4.3.1A), which serves as a proof of concept that the LCM-based proteomic 
approach reflects the significant diagnostic histochemical discrimination. This expression 
difference was strongly visible when we made analyses of the subunits of cytochrome oxidase 
(COX, complex IV) encoded by mtDNA. Further, we observed this for all respiratory chain 
subunits of mtDNA origin (Figure 4.3.1, right red boxes). Accordingly, COX+ muscle fibers 
of CPEO patients have been shown to contain more copies of mtDNA than the COX- 
counterparts [113]. Our study showed complex I subunits were significantly higher in COX+ 
than in COX- fibers (Figure 4.3.1B), however, complex III were essentially the same between 
COX+ and COX- fibers. Three out of four subunits of SDH (complex II), a histological 
marker of mitochondrial content, were more abundant in COX- fibers.  
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Figure	 4.3.1:	 Expression	 of	 respiratory	 chain	 complexes	 IV	 and	 I	 in	 COX+	 (orange)	 and	
COX-	 (blue)	 fibers.	Boxplots	are	superimposed	on	the	 individual	data	points.	Boxes	show	the	
mean,	 25th	 and	 75th	 percentile,	whiskers	 show	 the	 standard	 deviation.	 A:	 Expression	 of	 COX	
(complex	IV)	subunits.	B:	Expression	of	complex	I	subunits.	For	simplicity,	only	the	expression	of	
the	 core	 catalytic	 complex	 is	 shown	 in	 the	 graph.	 (The	median	 expression	 of	 each	 quantified	
protein	 of	 the	 complex	 in	 COX-	 and	 COX+	 fibers	 is	 shown	 by	 the	 graph	 on	 the	 right	 of	 each	
boxplot.	The	values	are	log10	scaled.)	
	
4.4 Potential molecular mechanisms of mitochondrial dysfunction at the cellular level 
 
Through the comparison between the proteomes of COX+ and COX- fiber pools of three 
CPEO patients using a Student’s t-test, the expression of 580 proteins exhibited significant 
statistic difference between the two groups (p<0.05). We performed a principal component 
analysis (PCA) for those significant mitochondrial proteins that showed a separation of the 
COX+ and COX- fiber pools along component 3 (Figure 4.4.1A). This process was driven by 
a specific enrichment of proteins annotated to the respiratory chain (p<10-7) in COX+ fibers. 
In contrast, Figure 4.4.1B shows COX- fibers displaying a high expression of the fatty acid 
binding protein 5 (FABP5) and of Wolframin (WFS1) which as an endoplasmic reticulum 
(ER)- transmembrane protein participates in calcium homeostasis. 
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Figure	 4.4.1:	 The	 separation	 of	 mitochondrial	 protein	 expression	 between	 the	 COX+	
(orange)	and	COX-	(blue)	fiber	pools.	A:	The	separation	showed	in	three	CPEO	patients.	B:	The	
separation	 showed	 in	 the	 highly	 significant	 enrichment	 of	 proteins	 annotated	 as	 respiratory	
chain	in	COX+	fibers.		
 
Then, we used Mitocarta 2 [114] to select the mitochondrial proteins from the dataset. The 
expression of all mitochondrial proteins was normalized by CS expression, which would 
correct differences in mitochondrial content between patients and mitochondrial number 
between samples. It contributed to analyze the features of mitochondrial proteomes of COX+ 
and COX- fiber pools. 109 proteins showed a highly significant expression in COX+ fibers 
annotating by the respiratory chain and electron transport performing >40-fold enrichments 
(Figure 4.4.2A). 49 Proteins with higher expression in COX- fibers displayed significant 
enrichments (> 25-fold) in annotations related to mitochondrial translation (Figure 4.4.2B). 
The increased expression of mitochondrial translation proteins might be regarded as a 
potential compensatory mechanism to offset the dysfunction of the respiratory chain in COX- 
fibers. 
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Figure	 4.4.2:	 Annotations	 of	mitochondrial	 proteins	with	 increased	 expression	 in	 COX+	
and	COX-	muscle	fiber	pools.	A:	COX+	fibers,	B:	COX-	fibers.	
 
We performed an unsupervised hierarchical cluster analysis of the mitochondrial proteins with 
significantly different expression between COX+ and COX- fibers (Figure 4.4.3).  These 
mitochondrial proteins were present in at least 2 of the 3 patients and filled any missing 
values by data imputation. In contrast to COX+ fibers, in COX- fibers, there were 29 up-
regulated mitochondrial proteins, including STOML2, PHB2 and OPA1 involved in cristae 
remodeling, mitochondrial fusion and respiratory supercomplex assembly, as well as the 
mitochondrial chaperones TRAP1 and HSD1.  In COX+ fibers, 82 proteins were up-regulated 
and related to oxidative phosphorylation and electron transport. These results suggest COX- 
fibers may compensate for the defective bioenergetic supply through up-regulating some key 
proteins in the process of mitochondrial network organization. 
 
 50 
 
 
Figure	4.4.3:	Hierarchical	cluster	analysis	of	the	mitochondrial	proteins	with	significantly	
different	 expression	 between	 COX+	 and	 COX-	 fibers.	The	differences	 in	 expression	of	 two	
clusters	clearly	separated	the	two	main	branches	of	the	dendrogram,	consisting	of	COX+	(orange)	
and	COX-	(blue)	fibers.	
 
4.5 Comparison of the mitochondrial proteome of individual CPEO patients 
 
Our LCM-based quantitative proteomic approach can elucidate the proteome bias caused by 
mitochondrial disease of each patient, implement analyses of mitochondrial proteomics in 
individual CPEO patients, and compare protein expression between COX+ and COX- fibers 
individually. In each patient, PCA showed a clear separation between COX+ and COX- fiber 
pools (in triplicates) along component one, which defines the largest difference in the dataset 
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(Figure 4.5.1A). In all CPEO patients, the separation was driven by a highly significant 
enrichment in components of the respiratory chain in COX+ fibers (p<10-9) while the drivers 
of the separation in COX- fibers were markedly heterogeneous (Figure 4.5.1B). These 
proteins could have some implication for potential clinical inference, since they may be 
involved in protective compensation reactions to mitochondria dysfunction in the specific 
patients. 
 
  
 
Figure	4.5.1:	Patient-specific	protein	expression	of	mitochondrial	diseases.	A.	Separation	
by	PCA	of	COX+	(orange)	and	COX-	(blue)	fiber	pools	of	each	patient.	B.		Corresponding	loadings	
driving	the	separation,	with	annotation	enrichments	and	p	values	indicated	by	arrows.	
 
Furthermore, we performed for each patient a T-test comparing COX+ and COX- fiber pools 
to highlight the significant differences in their mitochondrial proteome. 11 proteins with 
significantly higher expression in COX+ fibers were common to all three patients and over 
50-fold upregulated in annotations pertaining to the respiratory chain and electron transport. 
However, only one protein, component 1 Q subcomponent-binding protein (C1QBP/p32), was 
commonly upregulated in COX- fibers of all three patients, which is a ubiquitously expressed 
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protein localized predominantly in the mitochondrial matrix and with poorly characterized 
function.  
 
4.6 Mitochondrial protein analysis at the single fiber level 
 
Regional specificity is enabled to microscopically isolate defined cell types with specific 
biological information by the means of LCM approach, which conduces to obtain deeper 
proteome coverage. With the help of COX/SDH double-labeling histochemistry as a 
morphological reference, we excised 20 serial sections of individual muscle fibers (COX+ 
and COX-) from 10 µm cross-sections of muscle biopsies for each patient (Figure 4.2.1). 
With this procedure, each single fiber encompasses 400 µm of tissue. We isolated three 
COX+ and three COX- single fibers from each patient.  The serial sections of the same fiber 
were pooled and processed together for single-shot MS analysis. Previous studies have 
suggested that MS-based proteomics allows to directly quantify different myosin isoforms and 
thus determine fiber type [101].  
 
Skeletal muscles are heterogeneous tissues and classified in different fiber types based on 
their expression of myosin heavy chain (MHC) isoforms. Human slow-type 1 fibers contain a 
higher oxidative metabolism and more mitochondria than the fast-type 2A and 2X fibers, 
which are characterized by a higher expression of glycolytic enzymes [101]. Hence, we next 
focused on the mitochondrial proteome of pure slow-type 1 fibers, analyzing the expression of 
mitochondrial proteins that were expressed in at least 9 of 12 slow fibers (217 proteins). We 
could separate COX+ and COX- slow fibers along component 2, which was driven by the 
significantly different expression of respiratory chain components (Figure 4.6.1). Here, 
several mitochondrial proteins were found with higher levels of expression in COX- slow 
fibers, which had the key control effect on the architecture of the inner mitochondrial 
membrane.  
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Figure	4.6.1:	Mitochondrial	proteins	expression	in	single	slow-type	muscle	fiber.	A:	PCA	of	
mitochondrial	proteins	in	pure	slow	single	fibers.	The	fibers	from	three	patients	segregate	into	
COX+	 (orange)	 and	 COX-	 (blue)	 along	 component	 two.	 (b)	 Corresponding	 loadings	 with	
significant	enrichments	indicated	by	the	arrow.		
 
 
Comparing the abundance of these proteins in single COX+ and COX- slow-type 1 fibers, we 
found several proteins displayed a significantly higher expression in COX-slow-type 1 fibers 
(Figure 4.6.2). One of those proteins is the Dynamin-related GTPase OPA1, a key member of 
the mitochondrial contact site and cristae organizing system (MICOS) involved in cristae 
remodeling and fusion [115]. ATPase family gene 3-like 2 (AFG3L2) and Lon peptidase 
(LONP1) also present a significant overexpression in COX- slow-type 1 fibers. The former is 
a catalytic subunit of mitochondrial AAA protease, which degrades misfolded proteins, 
controls mitochondrial fragmentation and calcium dynamics [116, 117]. The latter is a master 
regulator of mitochondrial protein homeostasis, which is reported to regulate the important 
mtDNA structure factor, mitochondrial transcription factor A (TFAM). Two prohibitin family 
members, prohibitin 1 (PHB1) and PHB2, which are scaffolding proteins of the inner 
mitochondrial membrane and regulate the cell proliferation and cristae morphogenesis[118], 
were also significantly upregulated in COX- compared to COX+ slow fibers. And the 
mitochondrial folate enzyme serine hydroxy-methyl transferase 2 (SHMT2) was also with a 
higher expression, which controls the expression of respiratory chain enzymes [119].  
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Figue	4.6.2:	Comparison	of	mitochondrial	proteins	expression	between	COX-	(blue)	and	
COX+	(orange)	slow-type	fibers.	The	individual	data	point	(each	one	fiber)	are	superimposed	
to	the	box	plot	showing	the	median,	25th	and	75th	percentile.	Whiskers	show	standard	
deviation.	The	barred	square	shows	the	mean.		
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5. Discussion 
 
Mitochondrial disorders are multisystem diseases characterized by defects in the assembly 
and function of the mitochondrial respiratory chain. They often affect the structure and 
function of tissues or organs with higher energy demands resulting in defective oxidative 
phosphorylation (OXPHOS). Skeletal muscle is a frequent target tissue in mitochondrial 
disorders. More than 250 pathogenic mtDNA mutations have been reported currently, and the 
heteroplasmy level of them will decide the expression of disease-associated proteins and the 
severity of mitochondrial disorders. Patient muscles therefore acquire a heterogeneous 
composition of compensated COX+ and noncompensated COX- fibers, which can serve as a 
diagnostic signpost of mitochondrial disease. 
 
Mass spectrometry (MS)-based proteomics are typically used to provide identification and 
quantification of diverse proteins on the level of whole tissues or organs, but this also 
produces an averaging effect causing interference with the deeper biological analysis. Hence, 
it is becoming widely recognized that it is of advantage for the understanding of the tissue-
specific pathogenesis of individual diseases to isolate specific spatially defined regions or cell 
types of samples, thus contributing to the recognition of candidate biomarkers or potential 
therapeutic targets at molecular level. Laser capture microdissection (LCM) is an easy and 
practical approach to capture morphologically defined cell types preserving abundant 
biological information. In our study, we performed LCM of 10 μm sections of muscle fibers 
and combined it with a sensitive quantitative proteomic workflow featuring recent 
technological advances. Since skeletal muscles are composed of variable fractions of slow and 
fast fibers which have different contractile properties, mitochondrial content and general 
metabolic features, our approach focuses on the complete proteomic analysis at the level of 
single muscle fiber via LCM. 
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5.1 The workflow with laser capture microdissection and proteomic analysis 
 
Our study shows the feasibility of using skeletal muscle cells of COX+ and COX- fibers 
isolated by LCM for MS-based proteome analysis at both individual level and single fiber 
level. The summarized strategy is outlined in Figure 4.1. Here, we performed the approach of 
LCM to isolate serial sections of COX+ and COX- cells based on COX/SDH staining and 
collected these pure cells to make proteomic analyses that allowed the discovery of 
mitochondrial molecular properties and unknown disease-associated signal pathways. It was 
confirmed that LCM-based enrichment is ideal for the proteomic analysis[120, 121]. 
 
However, it is challenging to execute the analysis of quantitative proteomics via peptide 
labeling strategies because of minute amounts of samples yielded. Our LCM-based proteomic 
approach combines single-shot measurements of patient samples with a fixed resource 
consisting of extensively fractionated peptide libraries using label free quantification 
(MaxLFQ), which increases peptide and protein identification and can be queried with a 
broad spectrum of molecular and diagnostic questions. Our LCM-based workflow allowed the 
quantification of over 4000 proteins from <50ng of patient material in just 3 hours of 
measurement time, despite the dynamic range of the muscle fiber proteome driven by highly 
abundant sarcomeric proteins. This depth allowed us to conduct a detailed analysis of the 
muscle proteome, providing refined quantification of all respiratory complexes and almost 
complete coverage of the TCA cycle and mitochondrial translation.  
 
5.2. Advantages and Limitations of LCM 
 
The advantages of LCM are intuitively clear including speed, practicability, precision as well 
as versatility. We can excise thousands of interesting cells per cap in a short time frame 
through adjusting the proper laser spot size, microdissection speed and precision [122]. 
Structures of both the targeted regions and the residual tissues can remain intact and avoid the 
waste of samples. Therefore, various cell types can be isolated sequentially from the same 
tissue cross-section by LCM. The LCM approach can be applied to different cell or tissue 
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preparations, even those archival sections [123]. Furthermore, LCM can spatially define the 
interesting cells or regions via the traditional H&E or immunohistochemistry staining. In the 
end, the analysis of DNA, RNA and proteins will not be affected due to the protection of film 
and the use of low power laser. Banks et al. reported that profiles of proteins collected by 
LCM were close to those collected by conventional methods [124].  
 
There are only few limitations of LCM. Since coverslip can prevent films adhering interesting 
cells from dropping to the cap of tubes, all slides prepared to operate microdissection do not 
allow cover glasses on the surface of tissue sections. That is the main limitation of LCM. Due 
to the absence of a coverslip, there is a lower optical resolution in the slide that affect the 
precision of microdissection in the capture of specific cells from complex tissues without 
typically morphological characters. Section staining is an effective measurement to address it. 
Another limitation only occurring occasionally is failure to remove captured cells from the 
slide to the cap. That is typically caused by loss of cellular adherence to the PEN membrane 
which results from the lower laser energy or deficient dehydration of tissues. In spite of these 
limitations, LCM remains an ideal tool to rapidly collect a large number of interesting cells or 
tissue regions from heterogeneous tissues. 
 
5.3 The different proteome level between COX+ and COX- fibers 
 
In muscle, COX+ and COX- fibers coexist and show a mosaic distribution in patients with 
mtDNA-associated mitochondrial disease. Our results clearly show that COX+ and COX- 
fibers are significantly different at the proteome level. Despite expressing respiratory chain 
components at a significantly lower level than COX+ fibers, COX- fibers upregulate 
mitochondrial ribosome proteins and proteins involved in the control of translation. This 
change is likely a compensatory mechanism, since the upregulation of mitochondrial 
translation is associated with partial rescue of respiration [125]. COX- fibers also increase the 
expression of several mitochondrial chaperones and of stomatin-like protein 2 (STOML2), 
which organizes cardiolipin-enriched microdomains in the inner mitochondrial membrane and 
controls the assembly of functional respiratory supercomplexes [126]. Among the proteins 
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upregulated in COX- fibers, only the complement component 1 Q subcomponent-binding 
protein (C1QBP) was common to all patients analyzed. Mutations in C1QBP have recently 
been detected in a patient with mitochondrial cardiomyopathy [127] and furthermore, 
C1QBP-knockout (KO) mice show respiratory-chain deficiencies due to impaired 
mitochondrial protein synthesis [128]. While being in line with previous reports in cellular 
models of mitochondrial disease, our proteomic data now quantify the molecular changes 
induced by mtDNA mutation at the level of the direct targets of disease, the muscle fibers.  
 
Moreover, a number of mitochondrial proteins associated with mitochondrial quality control 
and mitochondrial dynamics were upregulated in COX- fibers. As discussed, mitochondrial 
quality control pathways are fundamental to numerous neurodegenerative diseases [129]. The 
pathogenesis of MELAS and LHON caused by mtDNA mutations for example, have been 
demonstrated to involve dysfunctions of mitochondrial protein quality control system [129-
131]. The enhancement of mitochondrial quality control is best perceived as a three-tiered 
mechanism to maintain the functionality of mitochondria [129]. The first line of defense 
involves chaperones, proteases and ubiquitin-proteasome system to sustain mitochondrial 
protein homeostasis at the molecular level. ATP-dependent protease Lon for example, a 
mitochondrial matrix protein, has been demonstrated to recognize and degrade various 
abnormal and damaged polypeptides [132]. Meanwhile, molecular chaperone proteins of the 
mitochondrial matrix, the Hsp60, Hsp70 and Hsp100 family, can stabilize misfolded proteins 
or mediate protein dissolution against aggregation [133]. The second mechanism is concerned 
with mitochondrial morphology and dynamic fission and fusion events to compensate for 
damaged mitochondria at the organelle level. The third mechanism focuses on clearance of 
damaged mitochondria and cells through mitophagy and apoptosis at the cellular level. In 
relation to the second mechanism, we found the dynamin-like GTPase OPA1 is significantly 
upregulated in COX- fibers. The dynamin-like GTPase OPA1 mediates mitochondrial fusion, 
ensuring cristae morphogenesis and the maintenance of mtDNA, and protection against 
apoptosis [134]. The overexpression of OPA1 is therefore likely to serve as an early response 
to maintain functional stabilization of mitochondrial network by preventing fragmentation of 
mitochondria [135]. 
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5.4 Proteomic analysis based on the level of individual muscle fiber 
 
The approach of laser capture microdissection (LCM), a powerful technique to precisely 
harvest the pure cell populations or cell regions targeted by morphology from heterogenous 
tissue sections and proteomics, can investigate the proteomic responses to mitochondrial 
dysfunction intra-individually, eliminating confounding bias. Additionally, since the clinical 
biopsies of patients with mitochondrial disease are routinely small in size and quantity, it is 
necessary to take full advantage of the limited tissues and cells available. Therefore, 
comparisons were made between COX+ and COX- cells not only on the whole samples but 
also on the single patient and single fiber type level in our study. Muscle fiber type 
abnormalities, including the distribution and size of type I and II fibers, have been reported in 
various mitochondrial diseases. In patients with adult mitochondrial myopathy, skeletal 
muscle fiber type transformation from type I to type II is described [136] and likewise, in a rat 
model of mitochondrial myopathy [137]. In contrast, type I fiber predominance has been 
demonstrated in children with mitochondrial myopathy. This predominance may serve as a 
compensatory mechanism for mitochondrial electron transport chain abnormalities as there is 
higher abundance of mitochondria in type I fibers compared to type II fibers, therefore they 
are able to partially enhance the energy production in damaged cells. The underlying 
pathogenesis of these changes in muscle fiber types however are poorly understood. 
 
The main feature of our LCM-based proteomic approach is the ability to analyze 
mitochondrial disease in individual muscle fibers, by following and cutting the same fiber 
across 20 serial muscle sections. In this pathological context, the heterogeneous composition 
of skeletal muscle into slow-type 1 and fast-type 2 fibers, which have different mitochondrial 
content, is superimposed onto the pathological process giving rise to the COX+ and COX- 
fiber mosaic. To reduce the variables causing this extreme heterogeneity we selected a pool of 
single muscle fibers defined as type-1 slow, based on the expression of MYH7, the slow 
myosin heavy chain isoform.  With this approach we eliminated confounding effects of the 
heterogeneous muscle fiber type composition, revealing a coordinated increase of the OPA1-
dependent cristae remodeling program in the mitochondria of COX- slow fibers. This 
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pathway controls the tightening of the mitochondrial cristae, which results in higher 
respiratory efficiency and limits the production of reactive oxygen species and cytochrome c 
release [138]. This fiber type-specific analysis also revealed that mitochondrial folate enzyme, 
serine hydroxyl-methyl transferase 2 (SHMT2), as specifically upregulated in COX- fibers. It 
has recently been shown that defects in this enzyme cause impaired expression of respiratory 
chain components by interfering with tRNA methylation and causing ribosome stalling [119]. 
 
5.5 Potential mechanisms of mitochondrial diseases 
 
Our data indicate that mitochondrial diseases are associated with complex proteomic 
rearrangements of the mitochondrial cristae affecting respiratory supercomplex formation and 
bioenergetic efficiency. Furthermore, our analysis also points to increased mitochondrial 
translation in COX- fibers. It remains to be determined whether the combination of the 
observed compensatory mechanisms ultimately provides rescue from the energy imbalance 
caused by respiratory chain defects, or whether it contributes to the pathogenesis of the 
disease by causing proteotoxic stress and inducing the mitochondrial unfolded protein 
response. Mechanistic studies of how defects in the assembly and function of the respiratory 
chain are communicated to the cell nucleus is necessary to understand the complex 
progressive pathogenesis of mitochondrial disease and to provide a molecular basis for 
targeted interventions. 
 
5.6 The prospect of clinical applications 
 
Precision medicine is defined as an approach to disease treatment and prevention that seeks to 
maximize effectiveness by considering individual variability in genes, environment, and 
lifestyle. Since mitochondrial diseases are highly heterogeneous in genetics, biochemistry and 
phenotype, this strategy has significant potential for their diagnosis and treatment. The high 
accuracy and sensitivity of mass spectrometry-based proteomics is well suitable to integrate 
proteomics into the developmental framework of precision medicine [139], and may help to 
bridge the gap between genotype and phenotype of diseases. The utilization of proteomic 
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technologies has resulted in great progress in precision medicine by facilitating detection of 
protein biomarkers, proteomics-based molecular diagnostics, as well as protein biochips and 
pharmacoproteomics [139]. Clinical proteomic-driven precision medicine has been reported 
in a range of diseases, such as in cancer, respiratory diseases, multiple sclerosis and diabetes 
[140-142]. However, applications in mitochondrial diseases have not been reported so far. 
 
Our group has established a fixed resource containing deep human skeletal muscle proteomes 
and built a streamlined LCM-based proteomics workflow applied to muscle biopsies and 
single muscle fibers. This will hopefully contribute to the development of precision medicine 
in mitochondrial diseases and provide novel insights in disease mechanisms, signaling 
pathways and sensitive biomarkers for molecular diagnosis and therapeutic monitoring. In 
conclusion, these findings have the potential to offer holistic insights into the molecular status 
of one individual, facilitate rapid and detailed diagnosis, as well as personalized prevention 
and therapy strategies. 
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6. Summary 
 
Mitochondrial disorders are multisystem diseases characterized by defects in the assembly 
and function of the mitochondrial respiratory chain, which usually attack skeletal muscles 
resulting in the mosaicism of COX+ and COX- fibers. Laser capture microdissection (LCM) 
is an effective tool to harvest specific cell types from heterogeneous tissues on the basis of 
histochemical staining. Combining LCM and mass spectrometry in the study of mitochondrial 
disorders opens the way for identification and analysis of proteins from specific cell or tissue 
types at the individual level.  
 
We designed an LCM-based proteomic workflow which can extract large amounts of 
biological information from minute amounts of frozen muscle biopsies, laser-microdissected 
muscle fiber sections and isolated single fibers in a short time. We utilized LCM to isolate 
COX+ and COX- cells from muscle biopsies of chronic progressive external ophthalmoplegia 
(CPEO) patients based on the combined cytochrome oxidase/succinate dehydrogenase 
(COX/SDH) staining, followed by their proteomic analysis at both the individual level and the 
single fiber level. Comparing these two muscle fiber types, we found COX+ and COX- fibers 
to be significantly different at the proteome level. COX- fibers upregulate the expression of 
mitochondrial ribosome proteins and proteins involved in the control of translation, which 
would be a compensatory mechanism in mitochondrial disorder. Moreover, the expression of 
optic atrophy protein 1 (OPA1) is likely to serve as an early response to maintain functional 
stabilization of the mitochondrial network. Moreover, we observed single fiber type-specific 
information showing that increased expression of fatty acid oxidation enzymes occurs in slow 
muscle fibers.  
 
Our study reveals compensatory mechanisms of skeletal muscle fibers for the energy deficit 
caused by mitochondrial dysfunction and suggests novel pathogenetic mechanisms in CPEO 
patients. The combination of LCM and quantitative proteomics may help to bridge the gap 
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between genotype and phenotype and to tackle unsolved questions in mitochondrial precision 
medicine. 
  
 64 
Zusammenfassung 
 
Mitochondriale Erkrankungen sind multisystemische Syndrome, die durch Defekte in der 
Zusammensetzung und Funktion der mitochondrialen Atmungskette gekennzeichnet sind. Sie 
betreffen häufig die Skelettmuskulatur und führen dort zu einem Mosaik aus Cytochrom c-
Oxidase-positiven (COX+) und –negativen (COX-) Fasern. Die Laser-Capture-
Mikrodissektion (LCM) ist ein effektives Werkzeug, um bestimmte Zelltypen aus 
heterogenen Geweben auf Basis einer histochemischen Färbung zu gewinnen. Die 
Kombination von LCM und Massenspektrometrie in der Erforschung von mitochondrialen 
Störungen eröffnet den Weg für die Identifizierung und Analyse von Proteinen bestimmter 
Zell- oder Gewebearten auf individueller Ebene.  
 
Wir haben einen LCM-basierten proteomischen Workflow entwickelt, der große Mengen an 
biologischer Information aus winzigen Mengen an gefrorenen Muskelbiopsien, laser-
mikrodissektierten Muskelfaserabschnitten und isolierten Einzelfasern in kurzer Zeit 
extrahieren kann. Wir haben LCM verwendet, um COX+ und COX- Zellen aus 
Muskelbiopsien von Patienten mit chronisch progressiver externer Ophthalmoplegie (CPEO) 
zu isolieren, basierend auf der kombinierten Färbung von 
Cytochromoxidase/Succinatdehydrogenase (COX/SDH), gefolgt von ihrer proteomischen 
Analyse sowohl auf individueller als auch auf Einzelfaserebene. Im Vergleich dieser beiden 
Muskelfasertypen haben wir festgestellt, dass COX+ und COX- Fasern auf Proteomniveau 
signifikant unterschiedlich sind. COX- Fasern hochregulieren die Expression von 
mitochondrialen Ribosomenproteinen und Proteinen, die an der Kontrolle der Translation 
beteiligt sind, was einen Kompensationsmechanismus bei mitochondrialen Störungen darstellt. 
Darüber hinaus ist die vermehrte Expression des Optic Atrophy-Proteins 1 (OPA1) 
wahrscheinlich eine frühe Regulation zur Aufrechterhaltung eines stabilen mitochondrialen 
Netzwerks. Darüber hinaus konnten wir eine erhöhte Expression von Fettsäureoxidations-
Enzymen in Typ 2-Muskelfasern beobachten.  
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Unsere Studie zeigt kompensatorische Mechanismen von Skelettmuskelfasern für das durch 
mitochondriale Dysfunktion verursachte Energiedefizit und ergibt Hinweise für neue 
pathogenetische Mechanismen. Die Kombination von LCM und quantitativer Proteomik kann 
dazu beitragen, die Lücke zwischen Genotyp und Phänotyp zu schließen und offene Fragen in 
der mitochondrialen Präzisionsmedizin zu beantworten. 
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7.2 Abbreviations 
 
ATP                                     Adenosine triphosphate 
ADT                                    Adenosine diphosphate 
ARE                                    Antioxidant responsive elements 
ADOA                                Autosomal dominant optic atrophy 
AFG3L2                             ATPase family gene 3-like 2 
ASC                                    Apoptosis-associated speck-like adaptor protein 
ACADS                              Acyl-CoA Dehydrogenase Short Chain 
AGC                                   Automatic gain control 
16-BAC                              16-benzyldimethyln-hexadecylammonium chloride 
CoQ                                     Coenzyme Q 
COX                                    Cytochrome oxidase 
CO                                       Cytochrome oxidase 
CPEO                                   Chronic progressive external ophthalmoplegia 
CTAB                                   Cetyl trimethylammonium bromide 
C1QBP                                 Component 1 Q subcomponent-binding protein 
D-loop                                  Displacement loop 
Drp1                                     Dynamin-related protein 1 
2DE                                      Two-dimensional 
ETC                                     Electron transport chain 
ETF                                     Electron transfer flavoprotein 
ER                                       Endoplasmic reticulum 
ESI                                      Electrospray ionization 
FABP5                                Fatty acid binding protein 5 
FAD                                    Flavin adenine dinucleotide 
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HSP60                                 Heat shock protein 60 
HCD                                    Higher-energy collisional dissociation 
IMM                                    Inner mitochondria membrane 
IL-1β                                    Interleukin-1β 
ICATs                                  Isotope-coded affinity tags 
iTRAQ                                 Isobaric tags for relative and absolute quantitation 
KSS                                      Kearns-Sayre syndrome 
LHON                                  Leber hereditary optic neuropathy 
LC-MS                                 Liquid chromatography coupled with MS 
LCM                                     Laser capture microdissection 
LONP1                                 Lon peptidase 
mtDNA                                 Mitochondrial DNA 
MELAS                                Mitochondrial encephalomyopathy with lactic acidosis and  
stroke-like episodes 
MERRF                                 Myoclonic epilepsy with ragged red fibers 
Mfn1                                      Mitofusin 1 
MS                                         Mass spectrometry 
MICOS                                  Mitochondrial contact site and cristae organizing system 
NRF-1                                    Nuclear respiratory factor-1 
nDNA                                     Nuclear DNA 
NLRP1                    Nucleotide-binding domain and leucine-rich repeat containing                      
proteins 1 
NLR                                        NOD-like receptor 
OMM                                      Outer mitochondria membrane 
O2                                                                  Oxygen 
OXPHOS                                Oxidative phosphorylation 
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OPA1                                      Optic atrophy protein 1 
PHB1                                       Prohibitin 1  
PLA2                                       Phospholipases A2 
PTMs                                       Post-translational modifications 
PCA                                         Principal component analysis 
rRNA                                       Ribosomal RNA 
ROS                                         Reactive oxygen species 
SDH                                         Succinate dehydrogenase 
SNO-Drp1                                S-nitrosylated Drp1 
SDS-PAGE                              Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SILAC                                      Stable isotope labeling with amino acids 
STOML2                                  Stomatin-like protein 2 
SHMT2                                     Serine hydroxyl-methyl transferase 2 
TCA                                          Tricarboxylic acid 
TFAM                                       Transcription factor A  
tRNA                                         Transfer RNA 
TM                                             Tansmembrane domain 
UPS                                            Ubiquitin–proteasome system 
UPRmt                                        Mitochondrial unfolded protein response 
VDAC                                        Voltage-dependent anion channel 
wt                                                Wildtype 
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